Morgan Stanley’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $117M | Sell |
25,891,480
-811,296
| -3% | -$3.55M | 0.01% | 1306 |
|
|
2025
Q4 | $128M | Buy |
26,702,776
+2,252,164
| +9% | +$10.1M | 0.01% | 1236 |
|
|
2025
Q3 | $111M | Buy |
24,450,612
+288,229
| +1% | +$1.06M | 0.01% | 1322 |
|
|
2025
Q2 | $74.7M | Buy |
24,162,383
+369,994
| +2% | +$1.23M | ﹤0.01% | 1563 |
|
|
2025
Q1 | $83M | Buy |
23,792,389
+1,205,471
| +5% | +$4.02M | 0.01% | 1384 |
|
|
2024
Q4 | $73.9M | Buy |
22,586,918
+878,467
| +4% | +$3.23M | 0.01% | 1486 |
|
|
2024
Q3 | $83.6M | Buy |
21,708,451
+748,183
| +4% | +$2.87M | 0.01% | 1384 |
|
|
2024
Q2 | $64.8M | Buy |
20,960,268
+12,129,971
| +137% | +$36.4M | 0.01% | 1505 |
|
|
2024
Q1 | $22.8M | Sell |
8,830,297
-5,137,927
| -37% | -$13.3M | ﹤0.01% | 2549 |
|
|
2023
Q4 | $34.9M | Buy |
13,968,224
+8,707,094
| +165% | +$17.1M | ﹤0.01% | 2824 |
|
|
2023
Q3 | $10.7M | Buy |
5,261,130
+180,834
| +4% | +$379K | ﹤0.01% | 3075 |
|
|
2023
Q2 | $11.7M | Buy |
5,080,296
+197,689
| +4% | +$515K | ﹤0.01% | 3024 |
|
|
2023
Q1 | $14.8M | Buy |
4,882,607
+4,640,713
| +1,918% | +$13.1M | ﹤0.01% | 2749 |
|
|
2022
Q4 | $564K | Buy |
241,894
+29,888
| +14% | +$71.5K | ﹤0.01% | 5179 |
|
|
2022
Q3 | $405K | Sell |
212,006
-6,948
| -3% | -$16.4K | ﹤0.01% | 5370 |
|
|
2022
Q2 | $595K | Buy |
218,954
+21,773
| +11% | +$55.7K | ﹤0.01% | 5328 |
|
|
2022
Q1 | $587K | Sell |
197,181
-41,826
| -17% | -$128K | ﹤0.01% | 5311 |
|
|
2021
Q4 | $930K | Buy |
239,007
+17,823
| +8% | +$69.2K | ﹤0.01% | 5124 |
|
|
2021
Q3 | $950K | Sell |
221,184
-70,597
| -24% | -$235K | ﹤0.01% | 5076 |
|
|
2021
Q2 | $884K | Sell |
291,781
-838,590
| -74% | -$2.6M | ﹤0.01% | 5151 |
|
|
2021
Q1 | $3.76M | Sell |
1,130,371
-291,893
| -21% | -$1.13M | ﹤0.01% | 3706 |
|
|
2020
Q4 | $5.05M | Sell |
1,422,264
-1,487,452
| -51% | -$5.21M | ﹤0.01% | 3247 |
|
|
2020
Q3 | $9.11M | Sell |
2,909,716
-443,821
| -13% | -$1.35M | ﹤0.01% | 2112 |
|
|
2020
Q2 | $6.1M | Buy |
3,353,537
+1,306,529
| +64% | +$2.14M | ﹤0.01% | 2466 |
|
|
2020
Q1 | $2.07M | Buy |
2,047,008
+175,920
| +9% | +$476K | ﹤0.01% | 3339 |
|
|
2019
Q4 | $5.2M | Buy |
1,871,088
+229,442
| +14% | +$371K | ﹤0.01% | 3168 |
|
|
2019
Q3 | $2.5M | Buy |
1,641,646
+31,760
| +2% | +$54.7K | ﹤0.01% | 3580 |
|
|
2019
Q2 | $3.35M | Buy |
1,609,886
+643,955
| +67% | +$1.65M | ﹤0.01% | 3321 |
|
|
2019
Q1 | $3.46M | Sell |
965,931
-119,644
| -11% | -$459K | ﹤0.01% | 3069 |
|
|
2018
Q4 | $4.16M | Buy |
1,085,575
+60,222
| +6% | +$297K | ﹤0.01% | 3096 |
|
|
2018
Q3 | $9.69M | Buy |
1,025,353
+289,556
| +39% | +$2.88M | ﹤0.01% | 2447 |
|
|
2018
Q2 | $5.37M | Buy |
735,797
+221,801
| +43% | +$1.32M | ﹤0.01% | 3065 |
|
|
2018
Q1 | $2.57M | Sell |
513,996
-114,681
| -18% | -$607K | ﹤0.01% | 3734 |
|
|
2017
Q4 | $3.17M | Buy |
628,677
+207,076
| +49% | +$1.21M | ﹤0.01% | 3576 |
|
|
2017
Q3 | $2.61M | Buy |
421,601
+94,353
| +29% | +$404K | ﹤0.01% | 3620 |
|
|
2017
Q2 | $1.18M | Buy |
327,248
+34,553
| +12% | +$119K | ﹤0.01% | 4253 |
|
|
2017
Q1 | $951K | Buy |
292,695
+14,695
| +5% | +$40.8K | ﹤0.01% | 4419 |
|
|
2016
Q4 | $681K | Buy |
278,000
+143,285
| +106% | +$417K | ﹤0.01% | 4731 |
|
|
2016
Q3 | $464K | Buy |
134,715
+34,862
| +35% | +$136K | ﹤0.01% | 4569 |
|
|
2016
Q2 | $347K | Buy |
99,853
+59,244
| +146% | +$251K | ﹤0.01% | 4628 |
|
|
2016
Q1 | $167K | Buy |
40,609
+18,591
| +84% | +$66.4K | ﹤0.01% | 5081 |
|
|
2015
Q4 | $98K | Sell |
22,018
-105,020
| -83% | -$576K | ﹤0.01% | 5416 |
|
|
2015
Q3 | $774K | Buy |
127,038
+27,758
| +28% | +$246K | ﹤0.01% | 4323 |
|
|
2015
Q2 | $1.18M | Buy |
99,280
+61,198
| +161% | +$931K | ﹤0.01% | 4074 |
|
|
2015
Q1 | $665K | Buy |
38,082
+8,801
| +30% | +$180K | ﹤0.01% | 4447 |
|
|
2014
Q4 | $444K | Sell |
29,281
-413,637
| -93% | -$7.14M | ﹤0.01% | 4747 |
|
|
2014
Q3 | $9.36M | Buy |
442,918
+417,570
| +1,647% | +$6.82M | ﹤0.01% | 2087 |
|
|
2014
Q2 | $331K | Sell |
25,348
-224,289
| -90% | -$3.18M | ﹤0.01% | 4882 |
|
|
2014
Q1 | $5.37M | Buy |
249,637
+248,158
| +16,779% | +$4.46M | ﹤0.01% | 2517 |
|
|
2013
Q4 | $12K | Buy |
+1,479
| New | +$12.3K | ﹤0.01% | 5996 |
|
Other funds holding ABUS
TSC
WCM
VCM
RCMNY
ACM
Morgan Stanley's ABUS Position: Q1 2026 in Review
Morgan Stanley reduced its Arbutus Biopharma (ABUS) stake by 3% in Q1 2026, selling an estimated $3.55M and leaving 25,891,480 shares worth $117M. The position accounts for 0.01% of the portfolio, ranked #1306.
Morgan Stanley first reported a position in ABUS in Q4 2013 and has held it in 50 quarters since. The position peaked at $128M in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.
- Morgan Stanley held 25,891,480 shares of Arbutus Biopharma worth $117M as of Q1 2026.
- Morgan Stanley sold 811,296 Arbutus Biopharma shares in Q1 2026, an estimated $3.55M.
- Arbutus Biopharma made up 0.01% of Morgan Stanley's portfolio in Q1 2026, its #1306 holding.
- Morgan Stanley first reported a position in Arbutus Biopharma in Q4 2013 and has held it in 50 quarters since.
- Morgan Stanley's Arbutus Biopharma position peaked at $128M in Q4 2025.
- 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.